Drugs / AGN-223575
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02155543 | May → Dec 2014 | — | Allergan | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02435914 | Jun 2015 → Jan 2016 | dry eye syndrome | Allergan | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AGN-223575 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02435914 ↗ |
| Route | Topical | “3 different doses of topical ophthalmic AGN-223575 suspension” NCT02435914 ↗ |